A Systematic Review of Risk Factors for Development, Recurrence, and Progression of Vulvar Intraepithelial Neoplasia

Objective Vulvar intraepithelial neoplasia (VIN) is a premalignant condition with high recurrence rates despite treatment. Vulvar intraepithelial neoplasia develops through separate etiologic pathways relative to the presence or absence of human papillomavirus (HPV) and TP53 mutations. This systematic review was conducted (1) to identify historical risk factors for the development, recurrence, and progression of VIN and (2) to critique these risk factors in the context of advances made in the stratification of VIN based on HPV or TP53 status. Materials and Methods A systematic search was performed on MEDLINE, Embase, Cochrane Database, PsychInfo, and CINAHL from inception to July 5, 2021. Three gynecologic oncologists independently evaluated the eligibility of studies based on predetermined inclusion and exclusion criteria, abstracted data, and then analyzed the relevant data. Results A total of 1,969 studies (involving 6,983 patients) were identified. Twenty-nine studies met inclusion criteria. The quality of evidence was low; primarily level 2b (Oxford Centre for Evidence-Based Medicine). Risk factors associated with the development of VIN include: smoking and coexisting vulvar dermatoses. Risk factors associated with recurrence include: smoking, multifocal disease, and positive surgical margins. Recent studies identified the presence of differentiated VIN/TP53 mutation as the most significant risk factor for both VIN recurrence and malignant progression. Conclusions The current body of evidence consists primarily of small retrospective observational studies. Well-designed retrospective case-control series and/or prospective observational studies are urgently needed. Ideally, future studies will collect standardized data regarding associated risk factors and stratify women with VIN based on HPV and TP53 status.

[1]  M. Schiffman,et al.  Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, Journal of lower genital tract disease.

[2]  J. Berkhof,et al.  Vulvar intraepithelial neoplasia: Incidence and long‐term risk of vulvar squamous cell carcinoma , 2020, International journal of cancer.

[3]  M. Schiffman,et al.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.

[4]  D. Huntsman,et al.  Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status , 2020, Modern Pathology.

[5]  C. Gilks,et al.  Vulval squamous cell carcinoma and its precursors , 2020, Histopathology.

[6]  A. Taylor,et al.  The Impact of Focality and Centricity on Vulvar Intraepithelial Neoplasia on Disease Progression in HIV+ Patients: A 10-Year Retrospective Study , 2019, Dermatology.

[7]  I. Vistad,et al.  Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review , 2018, International Journal of Gynecologic Cancer.

[8]  N. Hacker,et al.  Vulvar cancer in high‐income countries: Increasing burden of disease , 2017, International journal of cancer.

[9]  M. von Knebel Doeberitz,et al.  HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course , 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[10]  L. Liao,et al.  Epidemiology of vulvar neoplasia in the NIH-AARP Study. , 2017, Gynecologic oncology.

[11]  C. Lombardo,et al.  The association of pre-treatment HPV subtypes with recurrence of VIN. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[12]  J. McAlpine,et al.  p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  A. García-Jiménez,et al.  Vulvar intraepithelial neoplasia: clinical presentation, management and outcomes in women infected with HIV , 2016, AIDS.

[14]  M. Zinna,et al.  Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. , 2014, European review for medical and pharmacological sciences.

[15]  S. H. van der Burg,et al.  Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia , 2013, International Journal of Gynecologic Cancer.

[16]  Michael Mueller,et al.  Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia , 2013, Journal of gynecologic oncology.

[17]  F. Sopracordevole,et al.  Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five-year follow-up. , 2013, European review for medical and pharmacological sciences.

[18]  Jubilee Brown,et al.  Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. , 2012, Gynecologic oncology.

[19]  F. Amant,et al.  Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. , 2012, The journal of sexual medicine.

[20]  D. Mutch,et al.  Clinical and Pathologic Features of Vulvar Intraepithelial Neoplasia in Premenopausal and Postmenopausal Women , 2011, Journal of lower genital tract disease.

[21]  L. Massuger,et al.  Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. , 2009, European journal of cancer.

[22]  H. Honest,et al.  Differentiated-Type Vulval Intraepithelial Neoplasia Has a High-Risk Association With Vulval Squamous Cell Carcinoma , 2008, International Journal of Gynecologic Cancer.

[23]  Van Seters Vulvar Intraepithelial Neoplasia: New concepts and strategy , 2008 .

[24]  Christian Dannecker,et al.  Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. , 2006, Gynecologic oncology.

[25]  P. Judson,et al.  Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma , 2006, Obstetrics and gynecology.

[26]  A. Stewart,et al.  Vulvar Intraepithelial Neoplasia: Aspects of the Natural History and Outcome in 405 Women , 2005, Obstetrics and gynecology.

[27]  M. Carvalho,et al.  Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. , 2004, The Journal of reproductive medicine.

[28]  F. Frizelle,et al.  High‐grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989–1999 , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.

[29]  J. Hall,et al.  Sexual dysfunction following vulvectomy. , 2000, Gynecologic oncology.

[30]  S. Modesitt,et al.  Vulvar Intraepithelial Neoplasia III: Occult Cancer and the Impact of Margin Status on Recurrence , 1998, Obstetrics and gynecology.

[31]  T. Horn,et al.  Prognosis of vulvar dysplasia and carcinoma in situ with special reference to histology and types of human papillomavirus (HPV) , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[32]  V. Küppers,et al.  Risk factors for recurrent VIN. Role of multifocality and grade of disease. , 1997, The Journal of reproductive medicine.

[33]  A. Korn,et al.  Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1. , 1996, Gynecologic oncology.

[34]  M I Shafi,et al.  Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women , 1996, British journal of obstetrics and gynaecology.

[35]  J. Junge,et al.  Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. , 1995, Gynecologic oncology.

[36]  B. Ghiringhello,et al.  Biologic behavior of vulvar intraepithelial neoplasia. Histologic and clinical parameters. , 1993, The Journal of reproductive medicine.

[37]  J. Bock,et al.  Intraepithelial neoplasia in the vulvar region. , 1985, Gynecologic oncology.

[38]  C. Holschneider,et al.  Vulvar intraepithelial neoplasia: Risk factors for recurrence. , 2018, Gynecologic oncology.

[39]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[40]  A. D. de Craen,et al.  Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. , 2005, Gynecologic oncology.

[41]  A. Basta,et al.  Intraepithelial neoplasia and early stage vulvar cancer. Epidemiological, clinical and virological observations. , 1999, European journal of gynaecological oncology.